Spinal Muscular Atrophy Medicine Market Report
The report on the Global Spinal Muscular Atrophy Medicine Market is segmented by Disease Type (Type 1, Type 2, Type 3, Type 4), By Treatment (Gene therapy, Drug [Spinraza, RG7916, RG6083 (Olesoxime)]), By Route of Administration (Oral, Intrathecal), and Region. It also focuses on the COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global spinal muscular atrophy medicine market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The report on the Global Spinal Muscular Atrophy Medicine Market is segmented by Disease Type (Type 1, Type 2, Type 3, Type 4), By Treatment (Gene therapy, Drug [Spinraza, RG7916, RG6083 (Olesoxime)]), By Route of Administration (Oral, Intrathecal), and Region. ...
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Global Spinal Muscular Atrophy Medicine Market is projected to grow from USD 980.6 million in 2020 to USD 2,085.4 million by 2026 at a CAGR of over 13.4% during the forecast period.
Figure: Global Spinal Muscular Atrophy Medicine Market Size, 2020-2026 (USD Million)
Wish to receive a free sample report? Click here.
Spinal Muscular Atrophy (SMA) is a very rare genetic disorder that affects the part of the central nervous system that controls voluntary muscle movements. SMA is an autosomal recessive neurodegenerative genetic disorder that is characterized by atrophy and the weakening of muscles. It is one of the most common debilitating genetic disorders and a primary genetic cause of death among infants. It mainly affects approximately one in 10,000 live births across the globe.
Key players operating in the global spinal muscular atrophy medicine market are-
Rising incidence and awareness for spinal muscular atrophy has surged significantly which is likely to spur the need for efficient therapeutic options, resulting in better patient outcomes.
By treatment, the spinal muscular atrophy medicine market has been segmented into gene therapy and drug. Under these, the drug segment garnered the highest market share in 2020 and is likely to register a substantial CAGR during the review period. The SMA Foundation financed more than USD 60 Mn in drug development programs and essential drug discovery assets in 2015 that aimed at developing an effective SMA therapy. Also, Spinraza is the only medicinal drug approved for the treatment of SMA to date, further propelling the segment growth.
By region, North America accounted for the highest market share in 2020 and is estimated to grow at a steady CAGR during the assessment period.
The outbreak of the COVID-19 virus has considerably affected the spinal muscular atrophy medicine industry owing to stringent lockdown measures and restricted movement of people. The unprecedented outbreak of coronavirus (SARS-CoV-2) has overshadowed the SMA treatment industry. The funds received for R&D activities and drug development for SMA have been declining, as most of the funds have been used up for vaccine production for COVID-19.
Wish to learn more about this report? Request a sample here.
The following is a list of the customers that the Spinal Muscular Atrophy Medicine market aims to convert the most:
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The spinal muscular atrophy medicine market is expected to witness an impressive growth of 13.4% CAGR in the foreseeable future.
Biogen (The U.S), Ionis Pharmaceuticals, Inc. (The U.S), F. Hoffmann - La Roche Ltd (Switzerland), Avexis, Inc. (The U.S), Novartis AG (Switzerland), Cytokinetics, Inc. (The U.S), Pfizer Inc. (The U.S), Boehringer Ingelheim International GmbH (Germany), Regeneron Pharmaceuticals, Inc (The U.S) and Abbott (The U.S) are among the key players in the spinal muscular atrophy medicine market.
The spinal muscular atrophy medicine market is expected to reach USD 2,085.4 million in the coming years.
Growing awareness regarding SMA worldwide and a rising number of initiatives to enhance the treatment options for such rare diseases are the factors driving the growth of spinal muscular atrophy medicine market.
North America accounted for the highest share in the spinal muscular atrophy medicine market in 2020.
The drug segment garnered the highest share in the spinal muscular atrophy medicine market in 2020.
Spinal muscular atrophy medicine companies, Spinal muscular atrophy medicine vendors, R&D companies, Hospitals, Drug manufacturing companies are the spinal muscular atrophy medicine market.